The invention relates to a conditioned regulatory T cell population (Tregs) characterized by enhanced immunosuppressive potential (functionality) and a method of the potentiated Treg population production in vitro and their medical use in therapy of adverse immune responses especially such as graft rejection, allergic reactions, graft versus host disease (GVHD), exaggerated inflammatory responses and autoimmune diseases, including e.g. multiple sclerosis (MS) or rheumatoid arthritis (RA).

Tregs are a unique leukocyte subset that does not protect from infectious agents but controls activation of other immune cells. Despite Tregs account for *1% of peripheral blood lymphocytes they maintain self-tolerance (1). Lack of Tregs that is characteristic for immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (1PEX) leads to development of multiple autoimmune diseases and severe hypersensitivities (2). In addition, Tregs play crucial role for graft tolerance and survival (3), while their higher numbers in allogeneic hematopoietic stem cell grafts predict improved survival of the recipient after transplantation (4). Recently Tregs were shown to be essential for resolving atherosclerotic cardiovascular disease, including atherosclerotic plaque regression (5) Natural thymus derived CD4 ⁺ FoxP3 ⁺ Tregs present a large therapeutic potential. They inhibit inflammatory responses, ameliorate autoimmunity and at the same time do not impair physiological immune responses against pathogens, like known immunosuppressive drugs (6). Multiple cell populations are under Treg surveillance, including conventional T cells, B cells, monocytes/macrophages, dendritic cells (DCs), granulocytes, natural killer (NK) cells and mast cells. Therefore, Tregs are responsible for establishment and maintenance of peripheral tolerance (1), as well as tissue protection and regeneration (7). To fulfil this duty Tregs use a wide variety of mechanisms of action. However the most universal and crucial are: 1). suppression of target cell proliferation and 2). degradation of extracellular adenosine triphosphate (eATP), extracellular adenosine diphosphate (eADP) and extracellular adenosine monophosphate (eAMP) that leads to generation and accumulation of extracellular adenosine (eADO). Suppression of immune cell proliferation significantly ameliorates any immune response and enables the shift into immune tolerance. To achieve this goal and inhibit proliferation of conventional T cells, like effector T cells (Teffs) Tregs use a mechanism called interleukin 2 (IL-2) deprivation (8). IL-2 is a T cell mitogen. After antigen recognition activated T cells start to secrete IL-2 that acts in autocrine and paracrine manner, inducing their proliferation. Unlike other T cells, Tregs do not produce IL-2, but the cytokine is required for their function and survival. Therefore, Tregs are characterized by increased expression of IL-2 receptor a-chain (lL2Ra/CD25) that together with CD122 (1L2R0) and CD132 (!L2Ry) forms trimeric receptor which binds IL-2 with significantly higher-affinity, than dimeric IL2 receptor (1L2R) composed of CD122 and CD132 expressed by conventional T cells (9).

Another very universal mechanism of suppression of immune responses by Tregs is based on eATP degradation leading to generation of extracellular adenosine (eADO). Following tissue injury high amounts of ATP are released into extracellular space. When eATP binds to P2 receptors (virtually expressed on all immune cells) it induces cell activation and inflammatory responses (10). Therefore, inhibition of eATP-gated P2X receptors has been shown to halt lymphocyte activation, suppress both Thl and Thl7 cells and to promote Treg responses. Not surprisingly, the inhibition of eATP signalling was found to attenuate GVHD in animal model, downregulate alloimmune responses, expand Tregs and promote graft survival (11). eATP signalling can be limited by internal regulatory mechanisms that redirect immune response from activation to suppression leading to generation of eADO. In contrary to eATP, eADO binds to Pl receptors and exerts immunosuppressive effects (10). In canonical pathway adenosine is produced through the action of adenosinergic ectoenzymes expressed on the cell membrane: CD39- triphosphate diphosphohydrolase (NTPDase) 1 and CD73- 5’-nucleotidase (5’- NT). CD39 converts ATP into ADP and ADP into AMP, while CD73 dephosphorylates the latter to eADO (12). Both CD39 and CD73 are expressed by Tregs and are known to be crucial for their immunoregulatory function (1). It has been also reported recently that Treg expression of CD39 and its high potential for eATP degradation is crucial for development of operational tolerance after renal transplantation (13).

Mounting evidence has linked alterations in the generation of eADO from extracellular nucleotides by ectonucleotidases to the immunological disruption and loss of immune tolerance in autoimmunity (10). As eADO suppresses function and inhibits proliferation of various populations and subsets of immune cells, including T and B lymphocytes, NK cells, DCs, monocytes, and macrophages, stimulates release of anti-inflammatory cytokines (i.e., IL- 10) and inhibits the release of proinflammatory mediators (i.e., tumour necrosis factor a; TNF-a and nitric oxide) it plays a significant role in restoring immune homeostasis, preventing tissue damage and promotion of healing processes (14,12). Multiple reports indicate that the onset of autoimmune disorders is — at least partially — related to a disruption of the adenosinergic pathways and to a local defective production of eADO. Multiple studies reported the link between eADO production and pathogenesis and/or clinical outcome of multiple sclerosis (MS) (15-16), rheumatoid arthritis (RA) (17), juvenile idiopathic arthritis (JIA) (18), autoimmune uveitis (AU) (19), type 1 diabetes (T1DM) (20), renal diseases (21) and GVHD (22). In in the latest eADO was shown to selectively deplete alloreactive CD4 and CD8 T cells, preventing onset of GVHD, but preserving immunity to viruses and leukaemia (23).

Therefore, providing of in vitro expanded Tregs that not only express CD39 and CD73, but first of all, present robust activity of these surface enzymes leading to eADO accumulation is crucial for Treg based therapies. Such Tregs present robust functionality and their clinical use will be of the great therapeutic benefit. What sets the goal of the invention.

The he presented invention has been focused on the method of in vitro production of functionally potentiated Tregs . The team has been using Tregs for clinical therapies since 2008 and was the first who applied in vitro expanded Tregs for the treatment of GVHD in adults (NKEBN/458-310/2008) (24), then T1DM in children (TregVAC 1SRCTN06128462; TregVAC2.0EudraCT:2014-004319-35) (25), and subsequently MS (TregSM EudraCT:2014-004320-22) (26).

Currently, clinical trials that test therapeutic potential of Tregs have been conducted in multiple medical centres all over the world. In these studies Tregs are used for therapy and/or prevention of GVHD (e.g. Treg002EudraCT:2012-002685-12) (27), treatment of T1DM in adults (NCT01210664), therapy of amyotrophic lateral sclerosis (ALS; NCT04055623), tolerance induction in kidney (e.g. NCT02091232 and NCT02129881) and liver (ThRIL NCT02166177 and NCT01624077) recipients (26). Results of all these studies confirm that Treg treatment is safe and does not impair immune responses to foreign and dangerous antigens (e.g. viruses, bacteria, tumour cells) (6). However, therapeutic use of Tregs requires their isolation and ex vivo expansion before clinically relevant numbers are obtained. Therefore, inventors have work on Treg based therapies and have been struggling with the same technical problems associated with Treg isolation and culture. The first of these issues was the low purity of isolated population, that affected safety and efficacy of the treatment (24). The hurdle was solved by introduction of a cell sorter for Treg isolation, as described in EP2859092A1. Nevertheless, ex vivo Treg expansion is associated with significant loss of their immunosuppressive potential that directly diminishes efficacy of Treg based therapies (28).

In addition, Tregs derived from patients with pathologically altered immune responses (e.g. autoimmune diseases, allergies, GvHD) are characterized by impaired functionality (29). Therefore, Treg production for clinical therapy should optimally not only preserve their function during culture in vitro, but also enhance their therapeutic potential.

Currently, the most common method for Treg expansion is based on use of IL-2 and magnetic beads coated with anti-CD3 and anti-CD28 antibodies (CD3/CD28 beads) (30- 31). However, multiple groups reported that this method does not prevent loss of Treg phenotype and function over the time in vitro (28). Therefore, numerous research groups used to add rapamycin into the culture, as it was shown to keep high numbers of CD4 ⁺ FoxP3 ⁺ Tregs during expansion (32). However, recent studies confirm that the drug preferentially inhibits proliferation of conventional T cells (Teffs) that can contaminate Treg culture, but does not prevent loss of FoxP3 expression in natural Tregs during the second week of expansion (33). Noteworthy, presence of rapamycin was shown to be associated with 5-10-fold reduction in Treg proliferation (34). Landman S et al. used 5- aza-2'-deoxycytidine (DAC) a derivative of 5-Azacytidine which is therapeutically used in haematological malignancies and is DNA methyltransferase inhibitor (DNMTi). However, the group reported that in vitro activation of Tregs in the presence of DAC led to a significant inhibition of Treg proliferation. In addition, Treg activation in the presence of DAC led to increased interferon y (IFNy) expression and induction of a T helper-1 phenotype (Thl) (35). Another approach that has been tested in Treg culture also by our group was based on use of infliximab, an anti-TNFa (tumour necrosis factor a) antibody. We have found that presence of the drug in the culture medium preserved function of Tregs and their characteristic phenotype over time (36). In a different study we have indicated that mild hypothermia of 33°C is able to stimulate Treg proliferation and preserve their phenotype (31). Multiple groups have been tested the impact of retinoic acid on Tregs and reported that the compound sustained Treg stability under inflammatory conditions (37). However, all these approaches are distinct from the current invention.

The main goal of the invention was to condition Tregs to obtain modified Treg population in vitro with stronger therapeutic potential. Unexpectedly the goal was achieved by implementation of adipose tissue derived mesenchymal stem cells (ASCs) from nonrelevant allogeneic donors into Treg culture. Both cell types are cultured in direct cell-to-cell contact in the same physical compartment for cell culture - culture vessel, e.g. flask, well, etc. The direct coculturing leads to bilateral cell communication - cells communicate with each other via surface receptors and soluble mediators, thus modifying their environment and responses bilaterally. The unique cytokine cocktail secreted into the culture medium by Tregs and allogeneic ASCs as well as their direct mutual interactions condition (modify) Tregs, thus they demonstrate stronger therapeutic potential. This way modified Treg population according to the invention shows enhanced suppression of proliferation of conventional T cells and enhances accumulation of eADO known of its pro-tolerogenic and anti-inflammatory potential.

Patent application WO 2010/135255 Al disclosed a method for ex vivo expansion of CD4 ⁺ CD25 ⁺ Tregs during 3 weeks . In addition, the immunomagnetic methods of Treg isolation described in this patent resulted in low initial Treg purity (40-75% on day 0), thus consequently a percentage of FoxP3 ⁺ cells in the second week of the culture on average was equal to 40-50 %. The method of Treg production described in our patent application significantly differs. It is based on use of combination of immunomagnetic isolation and cell sorting with FACS (florescence activated cell sorter). This difference enables isolation of Tregs with median purity of 98%, thus post expansion purity is significantly higher (median % of CD4+FoxP3+ Tregs =90.15%), than it was described in the invention no. WO 2010/135255 Al. However, the main novelty of the current application is Treg coculture in direct contact with allogeneic ASCs that results in significant enhancement of Treg therapeutic potential.

Patent application US 2015/0104428 Al describes immunoregulatory effect of bone marrow derived mesenchymal stem cells (MSCs). The authors describe that MSCs after systemic infusion induce apoptosis of conventional T cells and increase Treg numbers in peripheral blood. This approach significantly differs from our invention too. In our approach mesenchymal stem cells are not isolated from bone marrow, but from adipose tissue (thus they are called ASCs) and are not supposed to be administered to the patients for induction of Treg responses. According to the present invention, ASCs are used for enhancement of Treg activity in vitro before the latest will be used for therapy. As ASCs are adherent cells they stay in the culture vessel attached to the bottom and only Tregs are collected for therapeutic use. In addition, in case of ASC contamination of the collected Treg product multiple methods for Treg purification exists, including FACS or immunomagnetic separation.

In the previous studies MSCs, including ASCs were used to induce immune suppression/tolerance by their direct administration to the patients (38), but not via stimulation of Treg function in vitro. Previously, the effect of MSCs on Tregs was demonstrated only in vivo. In addition there is lack of studies were MSCs or ASCs were cocultured with pure sorted Treg subset in direct contact.

Elaboration of a safe, simple to implement and economic method for expansion of stable Tregs characterised with potent suppressor activity is of key importance for advancement and success of clinical trials utilising Tregs as a therapeutic tool. Ability to regulate the immune response is important from the therapeutic point of view. Physiologically, the immune system recognises and destroys foreign and dangerous antigens, and tolerates self-tissues. Nevertheless, in autoimmune diseases, such as MS, T1DM, psoriasis, systemic lupus erythematosus (SLE) or RA this mechanism is impaired (25-26,39-42) and immune system begins to destroy the patient's own tissues, leading to irreversible changes. The current management of autoimmune diseases commonly involves nonantigen-specific immunosuppression and inhibition of inflammatory response. However, this kind of treatment emerges ineffective in long time perspective. Despite the initial improvement, progression of the disease cannot be completely stopped, while discontinuation of the treatment usually results in an exacerbation of the symptoms. Moreover, this treatment is associated with compromised immunity (43). Therefore, the patients become susceptible to various infections, which have much more severe manifestation, than in healthy individuals who are not treated with immunosuppressive drugs. Furthermore, non-specific immunosuppression increases the risk of cancer (higher prevalence of cancer in patients receiving immunosuppressants) (44).

Regulation of the immune response is also an important issue from the viewpoint of transplantation medicine. Organ transplantation is usually a life-saving procedure but is also associated with life-long treatment with potent immunosuppressive drugs. Discontinuation of this treatment results in increased immune response to the graft, which leads to its loss. The use of immunosuppressive drugs, as in therapy of autoimmune diseases, is associated with the risk of severe adverse effects. Furthermore, some of these drugs simultaneously protect the transplanted organ from the recipient immune system and are toxic for the graft or other tissues. Examples include nephrotoxic inhibitors of calcineurin (ciclosporin and tacrolimus) used in kidney transplantation (45) or rapamycin used in pancreatic islet recipients despite its deleterious impact on transplanted 0 cell function (46).

The problem of immunosuppression and regulation the of immune response is also closely associated with bone marrow transplantation. The principal difference between organ and bone marrow transplantation is that in the former case, medicine intends to protect the transplanted organ from the destructive action of the recipient's immune system, while in the latter case, there is no risk of transplant rejection but the transplanted bone marrow is a source of cells that attack the recipient's body and may lead to death (47). However, regardless of the origin of the immune cells attacking the patient's body, currently the fight against the excessive immune response is based on using of non-specific immunosuppression.

An apparently different issue is the excessive immune response to innocuous foreign antigens, as it is observed in various types of hypersensitivities that all together are used to be called allergies. Most of these disorders can be successfully treated symptomatically with the available medications. Nevertheless, in case of asthma the problem is more complex. The disease progresses with time, inflammation exaggerates leading to persistent structural changes in the airways and medical treatment become ineffective (48). Thus, there is need for novel therapeutic approaches.

To summarize, fully effective and safe drugs used for treatment of autoimmune and allergic diseases, as well as in transplant recipients would be those that target directly the mechanisms responsible for the disease onset or injury of the transplanted organ and at the same time would not impair the physiological immune response to foreign and dangerous antigens. A chance for so-called intelligent immunosuppression is offered by Tregs. However, the success of clinical therapy with Tregs depends on method for Treg production that will guarantee safety and enhanced suppressive potential of Tregs after culture in vitro (49). The method described in this patent application meets the above listed criteria and may be successfully used for the expansion of both polyclonal or antigen-specific Tregs for therapy and research approaches.

Unexpectedly, according to performed studies, authors of the current invention have demonstrated potentiation of Treg function by the culture in direct cell-to-cell contact with ASCs derived from allogeneic donors. The method enables to achieve Tregs characterized by significantly enhanced immunosuppressive activity - functionality - when ASCs from allogeneic donor are added into the same culture with Tregs. The main novelty of the invention is that:l). pure FACS sorted Tregs are expanded and conditioned in vitro in direct cell-to-cell contact with adipose tissue derived mesenchymal stem cells (ASCs) derived from allogeneic donor and 2). ASCs are not intended to be transferred to the patients, but used only for in vitro reinforcement of Tregs. In the current invention only Tregs conditioned by ASCs are dedicated for therapeutic use. In the presented example Treg functionality is being improved due to their communication with ASCs via surface receptors and soluble mediators. Importantly, in the current method of Treg expansion Tregs and ASCs modify their environment mutually and stimulate each other. As a result, the unique cytokine cocktail is secreted into the culture medium by Tregs and allogeneic ASCs. Subsequently this cytokine cocktail conditions (modifies) Tregs, thus they demonstrate stronger therapeutic potential, than Tregs cultured in conventional (known) monocultures. The described Treg population is therefore new - it is characterized by enhanced immunosuppressive potential (functionality).

The method according to the invention enables production of conditioned Tregs - the Treg population with enhanced functionality that are characterized by several advantages:

Higher proportion of FoxP3 ⁺ Tregs after 14 day culture (median 90.15%, range 83.2%- 93.4%) as compared with standard culture conditions (monoculture; median 83.7%; range 73.2%-88.7%).

Higher proportion of CD25 ^Hi § ^h Tregs at day 14 in vitro (median 93.9%, range 82.6%- 95.3%) as compared with standard culture conditions (monoculture; median 82.1%; range 58.1%-92.6%).

Higher proportion of CD73 ⁺ Tregs at day 14 in vitro (median 2.95%; range 1.9-6.5%) as compared with standard culture conditions (monoculture; median 1.8%, range 0.8- 2.7%). Enhanced inhibition of proliferation of conventional CD4 ⁺ T cells; the conditioned Tregs are significantly more potent inhibitors of proliferation of conventional CD4 ⁺ T cells (effector T cells, Teffs), than Tregs expanded in standard culture conditions (monoculture). Proliferation index of Teffs in presence of the conditioned Tregs is 21.77%, 17.53% and 15.37% (median) lower for 2:1, 1:1 and 1:2 Tregs:Teffs ratios, respectively as compared with the values observed for Tregs expanded in standard culture conditions (monoculture).

Enhanced degradation of eATP; 1 xlO ⁶ of conditioned Tregs degrades 44% (median) more nmol of eATP during 1 min, than Tregs expanded in standard culture conditions (monoculture).

Enhanced degradation of eAMP; 1 xlO ⁶ of conditioned Tregs degrades 402 % (median) more nmol of eAMP during 1 min, than Tregs expanded in standard culture conditions (monoculture). Degradation of eAMP leads directly to generation of eADO that is known immunosuppressive and protolerogenic mediator.

The main problem in Treg culture that has been reported in the state of the art is their progressive loss of characteristic phenotype of FoxP3 ⁺ CD25 ^Hi § ^h cells and immunosuppressive function during culture in vitro. However, the current invention enables to keep stable expression of FoxP3 and CD25 molecules in Tregs by implementation of ASCs into their culture. Tregs expanded according to the invention are characterized by significantly higher proportion of FoxP3 ⁺ cells after 14-day culture (median 90.15%) as compared with Tregs kept at standard culture conditions (monoculture) at day 7 (median 86.8%) and 14 (median 83.7%) of in vitro expansion. In addition, Tregs cultured in presence of ASCs showed higher frequency of CD25 ^Hi s ^h cells. As it was mentioned before, CD25 is an indispensable subunit of high affinity 1L2R. This indicates that the Tregs expanded in direct contact with ASCs can bind significantly more IL-2, than Tregs expanded in monoculture and thus show stronger potential for inhibition of proliferation and survival of conventional T cells via IL-2 deprivation mechanism.

The most important advantage of the invention are Tregs with significantly higher immunosuppressive potential than it is observed when the cells are expanded in accordance with the conventional known methods (monocultures). The provided example indicates that Tregs expanded in direct contact with ASCs are able to substantially suppress proliferation of conventional T cells (Teffs). Tregs conditioned with ASCs according to the method disclosed herein almost completely suppressed proliferation of target cells in the studied 2:1, 1:1 and 1:2 Treg: Teff ratios. At the same time both: 1). Tregs expanded alone in basic culture medium, as well as 2). Tregs cultured in medium supplemented with culture supernatants (SNs) collected from ASC monocultures were significantly less effective suppressors of Teff proliferation. This indicates that the culture protocol disclosed herein is a novel and very effective method of " Treg conditioning” that have very high therapeutic potential.

Previously, a demethylating agent 5-aza-2-deoxycytidine (DAC) was tested in Treg culture as the drug that can potentially preserve Treg phenotype and function. However, the compound was shown to suppress cell proliferation and induce expression of proinflammatory IFNy that can affect therapeutic potential of Tregs. While the current invention enables to overcome this problem, as Treg culture in direct contact with ASCs does not impair viability and significantly improves their therapeutic potential. Tregs expanded in presence of ASCs show enhanced potential for degradation of eATP and eAMP, and thus increased generation of immunosuppressive eADO. At the same time the direct contact of Tregs with ASCs does not increase eADO conversion to inosine (1NO), leading to its extracellular accumulation. As it was mentioned before eADO is one of the most important inducers of immune tolerance.

It is known that Tregs use CD39 and CD73 ectonucleotidases for degradation of ATP and AMP, respectively. Tregs expanded according to the method disclosed herein show increased activity of both CD39 and CD73 ectonucleotidases. In addition, the inventors showed and observed a negative correlation between Treg degradation of eATP (R=- 0.39; p=0. 01) and eAMP (R=-0.45; p=5xl0' ³ ) leading to accumulation of eADO and proliferation of Teffs in presence of these Tregs. The data indicate that the higher Treg potential for eADO accumulation is, the stronger suppression for Teff proliferation they demonstrate.

Thus, the basis of invention is that the therapeutic potential of Tregs can be enhanced significantly by conditioning them with the direct contact with allogeneic ASCs.

The present invention relates to the Tregs cell population and method of in vitro expansion of CD4 ⁺ FoxP3 ⁺ Tregs. According to the invention Treg expansion takes place in direct contact with allogeneic human ASCs that enables cell-to-cell interactions. Concomitantly, both cell types secrete soluble mediators that all together affect their phenotype and function.

The process of Treg expansion takes place permanently or temporarily but at least 3 days (72 hours) in direct contact with allogenic ASCs. Temporarily means that the Tregs and ASCs can be cultured separately and then coculture is performed or are cocultured together and then are separated into monocultures.

The advantages of the invention are presented in following figures and table.

Figure 1 is a chart showing % of FoxP3 ⁺ and CD25 ^Hi s ^h cells during expansion at tested culture conditions and intensity (median fluorescence intensity, MFI) of these markers expression by FoxP3 ⁺ and CD25 ^Hi § ^h cells, respectively.

Figure 2 is a chart showing % of CD39 ⁺ and CD73 ⁺ Tregs during expansion at tested culture conditions and intensity (MFI) of these markers expression by CD39 ⁺ and CD73 ⁺ cells, respectively.

Figure 3 is a chart showing representative histograms of Teff proliferation inhibition by Tregs expanded in tested culture conditions in 1:1 Treg:Teff ratio and depicts proliferation index (Pl) of Teffs stimulated with CD3/CD28 beads in presence of Tregs previously expanded alone in basic culture medium, in culture medium supplemented with ASC derived SNs and in direct contact with allogeneic ASCs in 2:1, 1:1 and 1:2 Treg:Teff ratios. For comparison the data for unstimulated autologous Teffs and bead stimulated Teffs cultured alone are presented as negative and positive controls, respectively.

Figure 4 is a chart showing degradation of extracellular ATP, AMP and adenosine by Tregs previously expanded in tested culture conditions. The data are shown in % as indexes. The fig. also presents correlations between eATP, eAMP and eADO degradation and suppression of Teff proliferation in proliferation inhibition tests. Proliferation of Teffs is presented as proliferation index. Table 1 is a table showing levels of 51 cytokines measured in supernatants collected after 24h and 48h from Treg monocultures, cocultures of Tregs and ASCs and from ASC monocultures.

The present invention is illustrated by the following example.

Example

Isolation of Tregs and CD4 ⁺ Teffs

Peripheral blood Tregs and CD4 ⁺ Teffs were isolated from buffy coats derived from female and male volunteer blood donors (n= 9) admitted to Regional Centre for Blood Donation and Treatment in Gdansk. First, peripheral blood mononuclear cells (PBMC) were obtained by Ficoll/Uropoline gradient centrifugation. Then, CD4 ⁺ T cells were isolated with negative immunomagnetic selection (isolation purity 90-99%). For this purpose, the EasySep Human CD4+ T Cell Enrichment Kit (Stemcell Technologies) was used. The kit depletes the samples from cells expressing the following antigens: CD8, CD14, CD16, CD19, CD20, CD36, CD56, CD66b, CD123, TCRy/8 and glycophorin A. Subsequently, the isolated CD4 ⁺ T cells were labeled with monoclonal antibodies (mAb, 5pl mAb/10 ⁶ cells) specific for the following antigens: CD3, CD4, CD25, CD127, CD8, CD 19, CD 16 and CD 14 (BD Biosciences). The last 4 mAbs were conjugated with the same fluorochrome in aim to minimize the fluorescence overlap and cut-off in one step cytotoxic T cells (Tc), B cells, NK cells and monocytes, respectively. These cells were defined all together in sorting algorithm as lineage.

Then, the cells were sorted with florescence activated cells sorter (FACS; Aria 11, BD Biosciences) into the following phenotype of Tregs: CD3 ⁺ CD4 ⁺ CD25 ^Hi g ^h CD127-/Lowd _ou biet-lineage- and Teffs: CD3 ⁺ CD4 ⁺ CD25-

CD127 ^Hi g ^h doublet ^_ lineage ^_ . The post-sort purity of Tregs was ~100% [median(min- max): 98%(97-99)]. The method for Treg culture according to the present invention, allow to replicate the results of Treg expansion also when different model of cell sorter or Treg isolation methods are used. Therefore, neither method of Treg isolation, nor the cell sorter used in this example are limitations of the present invention.

The isolated Tregs and Teffs were then seeded into separate plates and expanded at 37°C in X-vivo20 culture medium (Lonza) which meets GMP criteria. The medium was also supplemented with antibiotics (penicillin 100 U/ml; streptomycin 100 mg/ml), 10 % foetal calf serum (FBS) and interleukin-2 (IL-2; 2000 U/ml; Proleukin; Chiron, San Diego, CA). On the day 0 of the culture, magnetic beads coated with anti-CD3 and anti- CD28 antibodies (CD3/CD28 beads; Invitrogen; Carlsbad, CA) were added to the culture at a 1:0.6 cell: bead ratio. The beads mimic stimulation by antigen-presenting cells (APCs) and thus induce Treg proliferation. For the first 7 days Tregs were expanded in monocultures, while Teffs were expanded alone for the entire duration of the experiment (14 days). Teffs served as a control for Treg phenotype analysis and were used as target cells in proliferation tests. The type of culture medium, serum and CD3/CD28 beads are not the limitations of the current invention and can be replaced by other equivalent reagents known in the art and used for standard T cell culture.

Isolation of ASCs

ASCs were isolated from fresh samples of adipose tissue (50-200 ml) obtained during liposuction procedures from 9 healthy individuals who were unrelated with Treg and Teff donors. Then, samples were washed 3 times with PBS to remove contaminating debris and erythrocytes. Subsequently, the tissue was digested with digestion solution in 1:1 of digestion solution (ml): tissue mass (g) ratio at 37°C with gentle agitation to obtain single cell suspension. Composition of the digestion solution was as follows: 5% collagenase type 1 (Sigma-Aldrich; 5mg/ml), 19% of PBS and 1% of FBS. The collagenase was inactivated with an equal volume of LG-DMEM (PAA, Austria) containing 10% FBS, followed by filtration of the resulting cell suspension through a 100 pm nylon cell strainer (Falcon) in order to remove debris. The filtrate was centrifuged and washed with PBS. Then, the pellet was suspended in erythrocyte lysis buffer for 10 min. (at room temperature, RT) to remove erythrocytes. Subsequently, the cells were centrifuged (600g, 10 min.) and washed with PBS containing 4% FBS. Isolated cells represented an initial stromal vascular cell fraction (SVF) and were seeded at a density of 1 x 10 ⁵ cells/cm ² into 25cm ² flasks with vented caps (Corning Primaria) in LG-DMEM containing 10% FBS (37°C; 5% CO2). Following the first 5 days of initial plating, nonadherent cells were removed by intense washing and the remaining fibroblast-like adherent cells were maintained in LG-DMEM 10% FBS medium until they achieved 80-90% confluence (~7 days of initial cultivation).

Subsequently, the cells were harvested after trypsinization (0.025% trypsin/EDTA, Lonza) at 37°C for «3 min. Then, their potential for differentiation into osteoblasts, adipocytes, and chondroblasts under standard in vitro differentiation conditions was tested to confirm stem cell properties. Simultaneously, the remaining ASCs were seeded at density of ~7xl0 ³ cells/cm ² into 75cm ² flasks (Corning Primaria) and cultured for further experiments.

Treg coculture with ASCs

After reaching ~ 80% confluency ASCs in 2nd passage were harvested and analyzed with flow cytometry (LSRFortessa, BD Biosciences) to confirm a phenotype of mesenchymal stem cells. Only cultures where >95% of cells presented the following phenotype: CD105 ⁺ CD90 ⁺ CD73 ⁺ CD44 ⁺ CD45 HLA-DR- were planned to be used for further experiments. However, the required purity was reached each time and all isolated ASCs passed the quality control. Subsequently, ASCs and Tregs were seeded into 24-well plates (Corning Primaria; at 3:20 ASC:Treg ratio in 1000 pl of medium/well) in the following combinations:

1). Tregs Solo (2xl0 ⁵ cells/well)- control monoculture of Tregs.

2). ASCs Solo (3xl0 ⁴ cells/well)- control monoculture of ASCs.

3). ASCs SNs (3xl0 ⁴ cells/well)- monoculture of ASCs from which supernatant (SN) was collected daily and transferred into Treg culture(Tregs SNs).

4). Tregs SNs (2xl0 ⁵ cells/well)- Treg monoculture supplemented with SNs derived from ASCs (ASCs SNs).

5). Direct- coculture of Tregs (2xl0 ⁵ cells/well) and ASCs (3xl0 ⁴ cells/well)- the culture where both cell types were expanded together in the same culture well. Therefore, the cells communicated directly via cell-to-cell interactions, as well as through secreted soluble mediators that affected the Tregs and ASCs mutually.

In these experiments all cells were expanded in X-vivo20 (Lonza) medium supplemented with antibiotics, 10% FBS, IL-2 (2000 U/ml) and CD3/CD28 magnetic beads in 1:0.6 Treg:bead ratio. Each time ASCs in 3rd passage were used in these experiments. In case of condition no. 4 (Tregs SNs) every day 800 pl (80%) of the culture medium was removed without the cells and replaced with 800 pl of the medium collected from ASCs cultured in condition no. 3 (ASCs SNs). Then, fresh medium was added to the condition no. 3 to keep the volume of 1000 pl/ well. In addition, every 24h and 48h culture supernatants were collected from condition no. 1, 2 and 5 to compare cytokine secretion by Treg and ASC monocultures and Treg-ASC cocultures.

After 7 day expansion Tres and ASCs were collected counted, analyzed with flow cytometry and subjected for functional tests (proliferation test, analysis of eATP, eAMP and eADO degradation).

Phenotype control

On each 7th and 14th day after Treg isolation (before and after coculture with ASCs), samples of Tregs expanded in 3 tested conditions: 1). monocultures, 2). in direct contact with ASCs and 3). in medium supplemented with SNs derived from ASC monocultures were collected and labelled with monoclonal antibodies purchased from eBiosciences (unless otherwise stated) directed against the following antigens: CD4 (BD Biosciences), CD25 (BD Biosciences), CD127 (BD Biosciences), CD45RA (BD Biosciences), CD62L, Helios, FoxP3, HSP-60 (Abeam), HSP-70 (Abeam), HSP-90 (Abeam), CD39, CD73, CTLA-4, CD31 and Nrp-1 (neuropilin 1). Each time unstained cells served as negative control. All samples were treated with Foxp3 Staining Buffer Set (eBiosciences) to enable intracellular staining. Then, the cells were analysed with flow cytometer (LSRFortessa, BD Biosciences).

Tregs expanded in direct contact with allogeneic ASCs showed significantly higher frequency of FoxP3 positive cells (median 90.15%, range 83.2%-93.4%) as compared with Tregs from the standard monocultures (median 83.7%; range 73.2%-88.7%; Mann-Whitney U test, p=0.02) and monocultures supplemented with ASC derives SNs (median 84.8%; range 58.8%-93.4%). FoxP3 is considered to be a master regulator of Treg function, thus loss of its expression in vitro leads to loss of therapeutic properties of Tregs. Figure 1A shows % of FoxP3 ⁺ cells at day 7 (SOLO day 7) that preceded the coculture experiments to visualize time dependent changes in frequency of FoxP3 ⁺ cells in vitro. Only Tregs expanded with ASCs showed stable expression of FoxP3 during the 2 ^nd week of the culture (Fig.lA).

In addition, Tregs expanded in direct contact with allogeneic ASCs (DIRECT day 14) showed significantly higher % of CD25 ^Hi s ^h cells at day 14 after the isolation (CD25/lL2Roc; median 93.9%, range 82.6%-95.3%, n=9) than those cultured in standard conditions (monoculture, SOLO day 14, n=9, Mann-Whitney U test, p=0.04; median 82.1%; range 58.1-92.6% ). Differences in % of CD25 ^Hi § ^h cells between Tregs expanded in medium supplemented with SNs derived from ASC monocultures (SN day 14, n=9, median 89.9%, range 80.2-91.6%) and Tregs from standard monocultures did not reach statistical significance. High expression of CD25 is crucial for regulatory activity of Tregs. Capture of IL-2 via CD25 limits its availability for other immune cells and thus prevents their proliferation. No difference were found between tested Treg cultures in terms of expression of such Treg markers as CD39 (Fig.2 A-B), Helios, CTLA-4, CD127, CD45RA, CD62L, HSP-60, HSP-70, HSP-90, CD31 and Nrp-lln addition, expression of Helios (a marker of thymus derived Tregs) and CTLA-4 (an immunoregulatory molecule) was high and stable in all culture conditions. Each time median frequency of Helios ^4- and CTLA-4 ⁺ Tregs at day 14 reached «80 and 100%, respectively. Nevertheless, Tregs expanded in direct contact with ASCs (DIRECT day 14, n=9) showed higher frequency of CD73 ⁺ cells at day 14 after cell isolation (Fig.2 C; Mann-Whitney U test, p=0.02; median 2.95%; range 1.9-6.5%), than the cells cultured in standard conditions (SOLO day 14, n=9, median 1.8%, range 0.8-2.7%) and in medium supplemented with SNs collected from ASC monocultures (SN day 14, n=9, median 1.9%, range 0.7- 2.9%). In addition, Tregs from the cocultures at day 14 after isolation were characterized by higher frequencies of CD73 ⁺ cells (Mann-Whitney U test, p=5xl0' ³ ), than Tregs from 7-week monocultures (SOLO day 7). These data indicate that the expression of CD73 in Tregs increased in response to contact with ASCs during the culture in vitro.

Test of inhibition of Teff proliferation by Tregs

At day 7 of the coculture a proliferation inhibition assay was performed. Teffs were stained with 2 pM of Violet Proliferation Dye 450 (VPD-450; BD Horizon) for 15 min. at 37°C and mixed with unstained autologous Tregs derived from studied culture conditions in the following Treg:Teff ratios: 2:1, 1:1 and 1:2. Cells were cocultured for the next 4 days at 37°C in X-vivo20 medium supplemented with 10% FBS and CD3/CD28 beads in a 1:1 Teff:bead ratio. Simultaneously, VPD-450 stained and unstimulated Teffs were used as negative control (complete inhibition of Teff proliferation, n=6), while VPD-450 stained Teffs and stimulated with CD3/CD28 beads in 1:1 Teff:bead ratio with no Treg supplementation served as positive control (no Treg dependent inhibition, maximal proliferation of Tregs in the studied settings, n=6; Fig.3). After 4 days cells were collected and labeled with 7-amino-actinomycin D (7-AAD, BD Pharmingen) that binds to DNA of dead cells in aim to exclude dead cells from the analysis. Then the samples were evaluated with flow cytometry (LSRFortessa, BD Biosciences).

The data were analyzed as proliferation index (Pl) that is an average number of divisions that all responding cells have undergone since the initiation of the culture and was calculated with the following formula:

_ The total number of divisions _

The number of cells that went into division

The total number of divisions= (nl/2)*l + (n2/4)*2 + (n3/8)*3 + (n4/16)*4 +(n5/32)*5 n0= number of cells that did not divide nl= number of cells that divided once n2= number of cells that divided twice n3= number of cells that divided 3 times n4= number of cells that divided 4 times n5= number of cells that divided 5 times

The number of cells that went into division=

=The number of cells at start of the culture - nO

The number of cells at start of the culture= n0+ (nl/2) + (n2/4) + (n3/8) + (n4/16) +(n5/32)

Each time results for negative control correspond to the complete inhibition of Teff proliferation (lack of stimulation, Fig.3, Negative control), while results for the positive control correspond to proliferation of stimulated Teffs in absence of Tregs (lack of inhibition, Fig.3, Positive control). Tregs cultured in direct contact with ASCs were found to suppress proliferation of Teffs (lower Pl of Teffs, Fig. 3A histogram Direct Tregs:Teffs 1:1; Fig.3B triangles, n=6) much more efficiently, than those cultured in standard conditions (monocultures, Fig.4A histogram Solo Tregs:Teffs 1:1; Fig.3B squares, n=6; Mann-Whitney U test, 2:1 p=2xlO ³ ; 1:1 p=8xl0’ ³ and 1:2 p=2xl0’ ³ ) and Tregs from cultures supplemented with ASC derived SNs (Fig.3A histogram SN Tregs:Teffs 1:1; Fig.3B circles, n=6; Mann-Whitney U test, 2:1 p=0.01; 1:1 p=0.17 and 1:2 p=0.01). Pl of conventional CD4 ⁺ T cells (Teffs) in presence of the conditioned Tregs was 21.77%, 17.53% and 15.37% (median) lower for 2:1, 1:1 and 1:2 Tregs:Teffs ratios, respectively as compared with the values observed for Tregs expanded at standard culture conditions (monoculture). In addition, for the following Treg:Teff ratios 2:1, 1:1 and 1:2 Pl of Teffs exposed to Tregs conditioned in the cocultures was at least 45%, 36% and 30% lower, respectively than Pl of Teffs stimulated alone (positive control). Statistically significant differences (p<0.05) in Treg mediated suppression of Teff proliferation between Tregs derived from the cocultures and the Tregs from monocultures are marked with “*”. At the same time statistically significant differences in Treg mediated suppression of Teff proliferation between coculture derived Tregs and the Tregs from standard monocultures as well as monocultures supplemented with ASC derived SN were marked with"**".

Suppression of Teff proliferation by Tregs is crucial for their therapeutic effect. By the limitation of immune cell proliferation Tregs are able to restrain abnormal and/or detrimental immune responses, like autoimmunity, chronic inflammation, GVHD, allergic reactions or graft rejection.

Evaluation of eATP, eAMP and eADO degradation

After 7-day coculture, samples of Tregs expanded in direct contact with allogeneic ASCs, those from standard culture conditions (monoculture) and Tregs cultured in medium supplemented with ASC derived SNs were collected for assessment of their potential for degradation of eATP, eAMP, and eADO. The cells were distributed into 5 ml polystyrene tubes (IxlO ⁶ Tregs/tube), washed twice with Hank's balanced salt solution (HESS) and preincubated in 1 ml of HESS (pH 7.4) with HEPES (1.25 ml of HEPES/50 ml of HESS) and glucose (0.05 g of glucose/50 ml of HESS). At this step also EHNA (Ipl/lOOOpl HESS) was added into the tubes where degradation of eATP and eAMP was measured to block adenosine deaminase activity and cells were incubated for 15 min at 37°C with gentle agitation. Subsequently, eATP, eAMP, or eADO was added at a final concentration of 50 pM and 70 pl of supernatants were collected at 0, 5, 15 and 30 minute time points. During the incubation period the cells were kept at 37°C and gently agitated. Each time the collection of SNs was preceded by centrifugation step (2 min., 1500 RPM) to eliminate the risk of cell collection that could affect the final results. The SNs were frozen immediately and stored at -80°C until analysis of the concentration of nucleotides and their catabolites with high-performance liquid chromatography (HPLC). The concentration of nucleotides and their catabolites was analysed with reverse-phase HPLC. The chromatographic system consisted of a Thermo Finnigan Surveyor autosampler and MS pump with UV6000RP Detector (Thermo Finnigan, UK). The analytical column (150x2.1 mm) Kinetex C18 with a 2.6-|im particle size (Phenomenex, USA) was used. The following chromatographic conditions were applied: buffer A was 122 mM potassium dihydrogen phosphate, 26.4 mM dipotassium hydrogen phosphate, and 150 mM potassium chloride; buffer B was a 15% (v/v) acetonitrile in buffer A. The amount of buffer B changed from 0% to 1% in 0.1 min, 3% in 3.3 min, 35% in 7.3 min, 100% in 9 min to 11.5 min, and 0% B in 11.6 min. The reequilibration time was 3.4 min, resulting in a cycle time of 15 min between injections. The flow rate was 200 pl/min, and the volume of injection was 2 pl. The analytical column was maintained at 23°C. Peaks were monitored by absorption at 254 nm. Data were collected and processed by Thermo Scientific Xcalibur Software (v.2.0, ThermoScientific, USA). The activity of eATP, eAMP, and eADO degrading enzymes was measured in nmol/min/lxlO ⁶ cells.

The rates of eATP, eAMP and eADO degradations are depicted as INDEXes (Fig.4). The values reached by Tregs derived from monocultures were treated as a standard and thus set to 100% for each experiment. Consequently, the rates of eATP, eAMP and eADO hydrolysis by Tregs cultured in direct contact with ASCs and those expanded in medium supplemented with SNs derived from ASC monocultures were converted adequately for each experiment and are shown in % in relation to the standard.

Tregs expanded in direct contact with ASCs showed accelerated degradation of eATP (Fig.4A; n=4) and eAMP (Fig.4B; DIRECT; n=4) that are known meditators of inflammation as compared with Tregs expanded alone in basic culture medium (SOLO; n=4; Mann-Whitney U test, p=0.02 for degradation of both eATP and eAMP) and Tregs from monocultures supplemented with ASC derived SNs (SN; n=4; Mann-Whitney U test,p=0.02 for degradation of both eATP and eAMP). One million of conditioned Tregs degraded 44% (median) more nmol of eATP and 402% (median) more nmol of eAMP during 1 min., than Tregs expanded in standard culture conditions (monoculture) and 32.5% (median) more nmol of eATP and 369.5 % (median) more nmol of eAMP during 1 min., than Tregs from monocultures supplemented with ASC derived SNs (Fig.4A-B). When the lowest values were compared we observed that 1 xlO ⁶ of the conditioned Tregs degraded at least 35.7% more nmol of eATP and at least 103.7% more nmol of eAMP during 1 min., than Tregs expanded in monoculture. Simultaneously, Tregs expanded in direct contact with ASCs did not show accelerated degradation of eADO as compared with the two other tested conditions (Fig.4C). Therefore, direct contact with ASCs increased significantly Treg capacity for generation and accumulation of eADO. This biological effect is of great importance for Treg immunosuppressive potential and efficacy of Treg based therapy. In addition, enhanced degradation of eATP and eAMP into eADO was associated with stronger suppression of Teff proliferation that was manifested as a lower proliferation index of Teffs (Fig.4D-E; Spearman’s rank correlation, R= -0.39, p=0.01 and R=-0.45, p=5xl0’ ³ for eATP and eAMP degradation, respectively; correlation was calculated for all studied culture conditions and all tested Treg:Teff ratios together, n=36). No correlation was found between eADO degradation and suppression of Teff proliferation by Tregs (Fig.4F).

Analysis of cytokine secretion

Each 24h and 48h after plating of the cells, SNs were collected from the following culture conditions: 1). Treg monocultures (n=6), 2). ASCs monocultures (n=6), and 3). Treg-ASC cocultures (n=6), where both cell types were expanded in direct cell-to-cell contact. Immediately after collection SNs were frozen and stored at -80°C until analysis. Concentrations of 48 mediators: IL-21, HGF (hepatocyte growth factor ), IL-35, sCD40L, EGF (epidermal growth factor), eotaxin, FGF-2 (fibroblast growth factor), FLT-3L (FMS- like tyrosine kinase 3 ligand), fractalkine, G-CSF (granulocyte stimulating factor), GM- CSF (granulocyte-macrophage colony stimulating factor), GROcc ( growth-related oncogene a), IFNot.2 (interferon oc2), IFNy (interferon y), IL-loc, IL-10, IL-IRA (IL-1 receptor antagonist), IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, !L-12p40, !L-12p70, IL-13, IL-15, 1L-17A, 1L-17E/1L-25, 1L-17F, IL-18, IL-22, IL-27, IP-10 (interferon y- induced protein 10), MCP-1/CCL2 (monocyte chemoattractant protein- 1), MCP-3, M-CSF (macrophage colony-stimulating factor), MDC/CCL22 (macrophage-derived chemokine), MIG/CXCL9 (monokine induced by IFNy), MIP-loc/CCL3 (macrophage inflammatory protein-la), M1P-10, PDGF-AA (platelet-derived growth factor AA), PDGF-AB/BB, RANTES/CCL5 (regulated upon activation, normal T cell expressed and secreted), TGFoc (transforming growth factor a), TNFoc (tumour necrosis factor a), TNF0, VEGF-A (vascular endothelial growth factor A) were measured with Human Cytokine/Chemokine/Growth Factor Panel A 48 Plex Kit (Merck) and analyzed with luminex (MAGP1X, Merck Millipore) according to the manufacturer instructions. In addition levels of HGF (hepatic growth factor, B1OL1M), 1L21 (BioLegend), and 1L35 (B1OL1M) were measured with ELISA.

It was found that cytokine concentrations measured after 24h and 48h in supernatants from Treg (n=6) and ASC (n=6) monocultures differed significantly from each other (Table 1; Tregs Solo 24h, Tregs Solo 48h, ASCs Solo 24h, and ASCs Solo 24h, respectively) and from SNs derived from Tregs cultured in direct contact with ASCs (n=6; Table 1; Direct 24h and Direct 48h). Statistically significant differences between the groups were calculated with Mann-Whitney U test and p<0.05 for comparisons between Direct 24h vs Tregs Solo 24h v and Direct 48h vs Tregs Solo 48h are marked with in Table 1. At the same time p<0.05 for comparisons between Direct 24h vs ASCs Solo 24h and Direct 48h vs ASCs Solo 48h are marked with “§”. Analogically statistically significant (p<0.05) differences between Tregs Solo 24h vs ASCs Solo 24h and Tregs Solo 48h vs ASCs Solo 48h are marked with

These data show that each of the tested culture conditions present an unique microenvironment that affects Treg phenotype and function in a different manner. Notably, cytokine levels in SNs derived from Tregs cultured in direct contact with ASCs were not a sum of these cytokine concentrations in SNs derived from Treg and ASC monocultures, but deviated significantly from both. These data indicate that the microenvironment in the Treg-ASC cocultures was shaped by bidirectional interplay between these two cell types. At this point it has to be also mentioned that the results for all experiments were consistent, despite ASCs derived from allogeneic donors and each time Tregs and ASCs from different unrelated donors were cocultured. These observations justify using of allogeneic ASCs for enhancement of Treg therapeutic potential.

The present invention relates to the conditioned regulatory T cell population (Tregs) with following characterization and therapeutic potential, listed below:

Are characterized by significantly higher percentage of FoxP3 ⁺ cells and CD25 ^Hi § ^h (Fig. 1) cells as compared with Tregs expanded in standard culture conditions (monoculture). High and stable expression of FoxP3 during culture in vitro is associated with preservation of Treg therapeutic potential. High expression of CD25 (IL2Ra) makes Tregs more competitive for IL-2 binding and thus inhibits proliferation of conventional T cells (Teffs) by IL-2 deprivation.

Preserve high expression of CTLA-4, Helios and CD39 (Fig.2A).

The population is characterized by higher expression of CD73 ectonucleotidase, than the cells expanded in standard culture conditions (monoculture; Fig.2B) that makes them more efficient in eAMP degradation (Fig.4).

Present significantly stronger potential for restoring immune tolerance and suppression of deviant immune responses, than Tregs cultured in standard culture conditions (monocultures) and those from monocultures supplemented with ASC derived SNs.

The population is characterized by significantly enhanced degradation of proinflammatory eATP and eAMP resulting in accumulation of eADO- known to prevent autoimmunity and restore immune tolerance (Fig.4). The cells show significantly stronger inhibition of proliferation of conventional T cells (Fig.3) that is crucial for limitation of deviant immune responses (e.g. autoimmunity, graft rejection, allergic reactions, exaggerated inflammatory responses and GVHD).

The Tregs can be used for clinical therapies of adverse immune reactions that are defined as: autoimmune diseases, transplant rejection, allergic reactions, exaggerated inflammatory responses and graft-versus-host disease.

The Tregs are polyclonal or antigen-specific cells.

Features listed above are of great importance for efficacy of Treg based therapies. Only administration of fully functional Tregs can provide beneficial effect of Treg based therapy.

The present invention relates also to the method of conditioning and expansion of conditioned regulatory T cell population (Tregs) and is characterized by the following:

It enables to obtain Tregs with significantly stronger potential for restoring immune tolerance and suppression of deviant immune responses, than Tregs cultured in standard culture conditions (monocultures) and those from monocultures supplemented with ASC derived SNs.

The Tregs obtained with this method can be used for clinical therapies of adverse immune reactions that are defined as: autoimmune diseases, transplant rejection, allergic reactions, exaggerated inflammatory responses and graft-versus-host disease.

As compared to the previously described techniques for potentiation of Treg expansion/function the current method is cost effective as ASCs are obtained from adipose tissue of healthy unrelated donors. The adipose tissue is collected during liposuction procedure and thus is recognised as biological waste.

In the case of clinical application, the method enables to obtain better therapeutic effect due to production of Tregs with significantly higher immunosuppressive and tolerance inducing potential than in case of conventional methods. In addition, the final product does not contain traces of cytotoxic and potentially dangerous drugs used for Treg cultures in previously described protocols (e.g. azacytidine).

Table 1

References - state of the art.

1. D. A. Vignali, L. W. Collison, C. J. Workman, How regulatory T cells work. Nat Rev Immunol 8, 523-532 (2008).

2. E. Gambineri, T. R. Torgerson, H. D. Ochs, Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr Opin Rheumatol 15, 430-435 (2003). 3. N. Pilat et al., Treg-mediated prolonged survival of skin allografts without immunosuppression. Proc Natl Acad Sci U S A 116, 13508-13516 (2019).

4. R. D. Danby et al., High proportions of regulatory T cells in PBSC grafts predict improved survival after allogeneic haematopoietic SCT. Bone Marrow Transplant 51, 110-118 (2016).

5. M. Sharma et al., Regulatory T Cells License Macrophage Pro-Resolving Functions During Atherosclerosis Regression. Circ Res 127, 335-353 (2020).

6. N. Marek-Trzonkowska et al., Therapy of type 1 diabetes with CD4(+)CD25(high) CD127-regulatory T cells prolongs survival of pancreatic islets - Results of one year follow-up. Clinical Immunology 153, 23-30 (2014).

7. R. W. M. Kempkes, 1. Joosten, H. Koenen, X. He, Metabolic Pathways Involved in Regulatory T Cell Functionality. Front Immunol 10, 2839 (2019).

8. S. Letourneau, C. Krieg, G. Pantaleo, O. Boyman, IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. J Allergy Clin Immunol 123, 758-762 (2009).

9. T. Chinen et aL, An essential role for the IL-2 receptor in T(reg) cell function. Nat Immunol 17, 1322-1333 (2016).

10. M. Vuerich, R. P. Harshe, S. C. Robson, M. S. Longhi, Dysregulation of Adenosinergic Signaling in Systemic and Organ-Specific Autoimmunity. Int J Mol Sci 20, (2019).

11. E. Castillo-Leon, S. Dellepiane, P. Fiorina, ATP and T-cell-mediated rejection. Curr Opin Organ Transplant 23, 34-43 (2018).

12. F. Morandi, A. L. Horenstein, R. Rizzo, F. Malavasi, The Role of Extracellular Adenosine Generation in the Development of Autoimmune Diseases. Mediators Inflamm 2018, 7019398 (2018).

13. M. Durand et al., Increased degradation of ATP is driven by memory regulatory T cells in kidney transplantation tolerance. Kidney Int 93, 1154-1164 (2018).

14. L. Antonioli, C. Blandizzi, P. Pacher, G. Hasko, Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer 13, 842-857 (2013).

15. L. Airas, J. Niemela, G. Yegutkin, S. Jalkanen, Mechanism of action of IFN-beta in the treatment of multiple sclerosis: a special reference to CD73 and adenosine. Ann N YAcad Sci 1110, 641-648 (2007). 16. J. Niemela et al., IFN-beta regulates CD73 and adenosine expression at the blood-brain barrier. Eur J Immunol 38, 2718-2726 (2008).

17. R. S. Peres et al., Low expression of CD39 on regulatory T cells as a biomarker for resistance to methotrexate therapy in rheumatoid arthritis. Proc Natl Acad Sci U S A 112, 2509-2514 (2015).

18. S. Botta Gordon-Smith, S. Ursu, S. Eaton, H. Moncrieffe, L. R. Wedderburn, Correlation of low CD73 expression on synovial lymphocytes with reduced adenosine generation and higher disease severity in juvenile idiopathic arthritis. Arthritis Rheumatol 67, 545-554 (2015).

19. D. J. Lee, A. W. Taylor, Recovery from experimental autoimmune uveitis promotes induction of antiuveitic inducible Tregs. J Leukoc Biol 97, 1101-1109 (2015).

20. L. Antonioli, C. Blandizzi, B. Csoka, P. Pacher, G. Hasko, Adenosine signalling in diabetes mellitus-pathophysiology and therapeutic considerations. Nat Rev Endocrinol 11, 228-241 (2015).

21. C. Blume et aL, Autoimmunity in CD73/Ecto-5'-nucleotidase deficient mice induces renal injury. PLoS One 7, e37100 (2012).

22. H. Tsukamoto et al., Deficiency of CD73/ecto-5'-nucleotidase in mice enhances acute graft-versus-host disease. Blood 119, 4554-4564 (2012).

23. G. D. Whitehill et al., Adenosine Selectively Depletes Alloreactive T Cells to Prevent GVHD While Conserving Immunity to Viruses and Leukemia. Mol Ther 24, 1655- 1664 (2016).

24. P. Trzonkowski et al., First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells. Clin Immunol 133, 22-26 (2009).

25. N. Marek-Trzonkowska et aL, Administration of CD4(+)CD25(high)CD127(-) Regulatory T Cells Preserves beta-Cell Function in Type 1 Diabetes in Children. Diabetes Care 35, 1817-1820 (2012).

26. P. Trzonkowski et aL, Hurdles in therapy with regulatory T cells. Sci Transl Med 7, 304ps318 (2015).

27. M. Di lanni et al., Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 117, 3921-3928 (2011). 28. P. Hoffmann et al., Loss of FOXP3 expression in natural human CD4+CD25+ regulatory T cells upon repetitive in vitro stimulation. Eur J Immunol 39, 1088-1097 (2009).

29. A. Visperas, D. A. Vignali, Are Regulatory T Cells Defective in Type 1 Diabetes and Can We Fix Them? J Immunol 197, 3762-3770 (2016).

30. J. A. Bluestone et al., Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med 7, 315ral89 (2015).

31. N. Marek-Trzonkowska et al., Mild hypothermia provides Treg stability. Sci Rep 7, 11915 (2017).

32. N. Safinia et al., Cell Therapy in Organ Transplantation: Our Experience on the Clinical Translation of Regulatory T Cells. Front Immunol 9, 354 (2018).

33. A. L. Putnam et al., Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes 58, 652-662 (2009).

34. K. L. Hippen et al., Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med 3, 83ra41 (2011).

35. S. Landman et aL, DNA Methyltransferase Inhibition Promotes Thl Polarization in Human CD4(+)CD25(high) FOXP3(+) Regulatory T Cells but Does Not Affect Their Suppressive Capacity. J Immunol Res 2018, 4973964 (2018).

36. M. Ryba et aL, Anti-TNF rescue CD4(+)Foxp3(+) regulatory T cells in patients with type 1 diabetes from effects mediated by TNF. Cytokine 55, 353-361 (2011).

37. Z. M. Liu, K. P. Wang, J. Ma, S. Guo Zheng, The role of all-trans retinoic acid in the biology of Foxp3+ regulatory T cells. Cell Mol Immunol 12, 553-557 (2015).

38. M. Pikula, N. Marek-Trzonkowska, A. Wardowska, A. Renkielska, P. Trzonkowski, Adipose tissue-derived stem cells in clinical applications. Expert Opin Biol Ther 13, 1357-1370 (2013).

39. V. Senecal et aL, Production of IL-27 in multiple sclerosis lesions by astrocytes and myeloid cells: Modulation of local immune responses. Glia 64, 553-569 (2016).

40. X. T. Lima et al., Frequency and characteristics of circulating CD4(+) CD28(null) T cells in patients with psoriasis. Br J Dermatol 173, 998-1005 (2015).

41. Q. Mu, H. Zhang, X. M. Luo, SLE: Another Autoimmune Disorder Influenced by Microbes and Diet? Front Immunol 6, 608 (2015). 42. W. Orent et al., Rheumatoid arthritis-associated RBPJ polymorphism alters memory CD4+ T cells. Hum Mol Genet 25, 404-417 (2016).

43. S. Gupta, Immunotherapies in diabetes mellitus type 1. Med Clin North Am 96, 621-634, xi (2012).

44. 1. Rama, J. M. Grinyo, Malignancy after renal transplantation: the role of immunosuppression. Nat Rev Nephrol 6, 511-519 (2010).

45. A. Prokai et al., Calcineurin-inhibition Results in Upregulation of Local Renin and Subsequent Vascular Endothelial Growth Factor Production in Renal Collecting Ducts. Transplantation 100, 325-333 (2016).

46. T. Berney, A. Secchi, Rapamycin in islet transplantation: friend or foe? Transpl lnt 22, 153-161 (2009).

47. K. Zhao et al., Dynamic regulation of effector IFN-y-producing and IL- 17- producing T cell subsets in the development of acute graft-versus-host disease. Mol Med Rep 13, 1395-1403 (2016).

48. R. A. Panettieri, Jr., R. Covar, E. Grant, E. V. Hillyer, L. Bacharier, Natural history of asthma: persistence versus progression-does the beginning predict the end? J Allergy Clin Immunol 121, 607-613 (2008).

49. Q. Tang, J. A. Bluestone, Regulatory T-cell therapy in transplantation: moving to the clinic. Cold Spring Harb Perspect Med 3, (2013).